Dechra Pharmaceuticals Future Growth

Future criteria checks 4/6

Dechra Pharmaceuticals is forecast to grow earnings and revenue by 62.5% and 7.9% per annum respectively. EPS is expected to grow by 89.8% per annum. Return on equity is forecast to be 19.8% in 3 years.

Key information

62.5%

Earnings growth rate

89.8%

EPS growth rate

Pharmaceuticals earnings growth	19.7%
Revenue growth rate	7.9%
Future return on equity	19.8%
Analyst coverage	Low
Last updated	03 Jan 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:DPHL - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	954	187	N/A	N/A	1
6/30/2025	904	123	160	182	5
6/30/2024	837	102	142	163	2
6/30/2023	762	-28	33	64	N/A
3/31/2023	744	6	39	75	N/A
12/31/2022	727	40	45	86	N/A
9/30/2022	704	49	45	105	N/A
6/30/2022	682	58	45	123	N/A
3/31/2022	661	66	48	121	N/A
12/31/2021	641	73	51	119	N/A
9/30/2021	624	64	3	104	N/A
6/30/2021	608	56	-45	89	N/A
3/31/2021	587	50	-45	102	N/A
12/31/2020	566	44	-44	114	N/A
9/30/2020	541	39	7	110	N/A
6/30/2020	515	34	57	106	N/A
3/31/2020	507	31	57	91	N/A
12/31/2019	499	29	57	76	N/A
9/30/2019	490	30	58	79	N/A
6/30/2019	482	31	59	82	N/A
3/31/2019	463	28	61	82	N/A
12/31/2018	444	25	62	81	N/A
9/30/2018	426	30	57	73	N/A
6/30/2018	407	36	51	64	N/A
3/31/2018	394	40	57	69	N/A
12/31/2017	381	43	63	75	N/A
9/30/2017	370	35	65	76	N/A
6/30/2017	359	26	67	77	N/A
3/31/2017	334	19	N/A	69	N/A
12/31/2016	309	11	N/A	62	N/A
9/30/2016	278	12	N/A	53	N/A
6/30/2016	248	13	N/A	44	N/A
3/31/2016	230	17	N/A	43	N/A
12/31/2015	213	20	N/A	42	N/A
9/30/2015	208	20	N/A	42	N/A
6/30/2015	203	19	N/A	41	N/A
3/31/2015	201	21	N/A	41	N/A
12/31/2014	199	22	N/A	42	N/A
9/30/2014	196	21	N/A	27	N/A
6/30/2014	194	19	N/A	11	N/A
12/31/2013	193	14	N/A	25	N/A
9/30/2013	191	13	N/A	31	N/A
6/30/2013	189	11	N/A	37	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DPHL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: DPHL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DPHL is expected to become profitable in the next 3 years.

Revenue vs Market: DPHL's revenue (7.9% per year) is forecast to grow faster than the UK market (3.8% per year).

High Growth Revenue: DPHL's revenue (7.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DPHL's Return on Equity is forecast to be low in 3 years time (19.8%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/01/17 10:01
End of Day Share Price	2024/01/15 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dechra Pharmaceuticals PLC is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Samuel England	Berenberg
Laurent Gelebart	BNP Paribas Exane
Brian White	Cantor Fitzgerald Europe

Dechra Pharmaceuticals Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021